Dr Michael Baker interview with The Stock Network
Ahead of appearing at the Spark+ Australian Equities Day in Singapore, Arovella's (ASX:ALA) CEO & Managing Director Dr Michael Baker speaks with The Stock Network’s Lel Smits about:
The current lead product coming out of Arovella Therapeutics’ cell therapy platform - ALA-101 - iNKT cells create receptors that target antigens
How ALA-101 targets cancers and tumours
Timing of Phase 1 trials for ALA-101
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697